StoneX (SNEX) Q3 2026 Earnings Call Transcript

StoneX Group reported Q3 FY26 net operating revenues of $719.7M (+47% YoY) and net income of $127.9M (+102% YoY), driving diluted EPS of $1.00 (+85% YoY; adjusted for a 3-for-2 stock split). ROE was 18.4% (above a 15% target), and the quarter benefited from R.J. O’Brien/Benchmark integration with segment growth across Commercial (+90% N.O. revenue YoY) and Institutional (+56%). Management also confirmed further $750M fixed-rate SOFR swaps this quarter (aggregate $2.55B, avg rate 3.51%) and raised/updated cost-synergy run-rate expectations to ~$37–$38M exiting Q3 and mid-$40Ms ($45–$46M) by end of fiscal Q4, targeting ~$50M by early FY27 Q1; shares began trading on a split-adjusted basis in late July.

Analysis

The key market mechanism is that SNEX is no longer trading like a cyclical broker; it is increasingly a balance-sheet and client-asset compounding story. The combination of acquisition integration, higher client balances, and better monetization of financing/clearing means revenue can keep growing even if market volatility cools, but the next leg of upside depends on cross-sell conversion rather than headline activity. That shifts the stock from “volume beta” to “execution beta,” which should support multiple expansion if management keeps proving that the platform raises share-of-wallet faster than costs rise.

Winners are the product lines that benefit from fragmentation and institutional dislocation: OTC, listed derivatives, physical commodities, and prime services. The second-order loser set is more subtle: smaller FCMs, niche prime brokers, and mid-market banks that cannot match SNEX’s multi-product offering or financing depth may see wallet share leak. If this ecosystem thesis holds, the real moat is not trading revenue; it is client stickiness created by collateral, custody, and payments integration, which should also improve deposit-duration economics for the next 6-18 months.

The main risks are timing and rate sensitivity. Near term, the stock can stall if volatility normalizes faster than cross-sell ramps, or if investors decide the acquisition uplift is being over-credited before synergy dollars fully convert. A 100 bp cut in short rates is a meaningful earnings headwind, so the market will likely punish SNEX if the Fed turns dovish while client balances stop compounding. The thesis is falsified if Q4 shows synergies and client balances flattening, or if payments/retail weakness spreads into the higher-value institutional franchises.

Key Decisions for Investors

• Long SNEX on pullbacks over the next 1-2 weeks; target a 3-6 month hold into the next integration milestone, with the thesis invalidated if client balances or ROE decelerate materially.
• Pair trade: long SNEX / short IBKR over 3-6 months to isolate M&A and cross-sell acceleration versus a cleaner, less acquisition-dependent brokerage comp model.
• Use SNEX call spreads rather than outright stock if chasing momentum: the upside is in synergy delivery and ecosystem monetization, but rate-cut sensitivity caps the near-term multiple expansion.
• Set a risk alert on 2H rate-cut repricing: if front-end yields fall sharply, trim SNEX because annualized net income sensitivity is large enough to offset part of the operating leverage.
• Watch for confirmation in the next quarter on OTC and Prime Services conversion; if those do not re-accelerate, treat the current strength as a one-quarter integration pop rather than a durable rerating.